Capital International Sarl raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,107 shares of the biopharmaceutical company’s stock after buying an additional 782 shares during the quarter. Capital International Sarl’s holdings in Gilead Sciences were worth $2,606,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in GILD. Capital Research Global Investors grew its holdings in Gilead Sciences by 10.9% during the 4th quarter. Capital Research Global Investors now owns 85,132,885 shares of the biopharmaceutical company’s stock valued at $5,531,935,000 after buying an additional 8,343,863 shares during the last quarter. Valueworks LLC grew its holdings in Gilead Sciences by 7,777.5% during the 4th quarter. Valueworks LLC now owns 4,919,000 shares of the biopharmaceutical company’s stock valued at $6,146,000 after buying an additional 4,856,556 shares during the last quarter. AQR Capital Management LLC grew its holdings in Gilead Sciences by 59.2% during the 4th quarter. AQR Capital Management LLC now owns 7,208,716 shares of the biopharmaceutical company’s stock valued at $464,529,000 after buying an additional 2,682,046 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Gilead Sciences by 15.1% during the 4th quarter. Renaissance Technologies LLC now owns 16,962,944 shares of the biopharmaceutical company’s stock valued at $1,102,252,000 after buying an additional 2,228,686 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Gilead Sciences by 26.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,615,468 shares of the biopharmaceutical company’s stock worth $429,872,000 after purchasing an additional 1,392,639 shares during the last quarter. Hedge funds and other institutional investors own 80.32% of the company’s stock.
Shares of GILD traded up $2.13 during trading hours on Thursday, hitting $71.79. The stock had a trading volume of 898,412 shares, compared to its average volume of 30,795,556. The company has a debt-to-equity ratio of 1.02, a quick ratio of 3.01 and a current ratio of 3.10. The firm has a market cap of $90.65 billion, a P/E ratio of 16.99, a P/E/G ratio of 5.79 and a beta of 0.99. The company’s fifty day simple moving average is $71.37 and its 200 day simple moving average is $66.57. Gilead Sciences, Inc. has a 12-month low of $60.89 and a 12-month high of $85.97.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $1.30 EPS for the quarter, missing the consensus estimate of $1.67 by ($0.37). Gilead Sciences had a net margin of 23.99% and a return on equity of 35.49%. The company had revenue of $5.88 billion during the quarter, compared to analysts’ expectations of $5.74 billion. During the same period last year, the business earned $1.44 earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 6.03 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.68 dividend. The ex-dividend date of this dividend is Thursday, March 12th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.63. This represents a $2.72 annualized dividend and a yield of 3.79%. Gilead Sciences’s dividend payout ratio (DPR) is 44.30%.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 2,950 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $64.63, for a total value of $190,658.50. Following the transaction, the executive vice president now directly owns 20,014 shares of the company’s stock, valued at $1,293,504.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Brett A. Pletcher sold 5,000 shares of the firm’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $68.18, for a total value of $340,900.00. Following the completion of the transaction, the executive vice president now directly owns 29,690 shares in the company, valued at $2,024,264.20. The disclosure for this sale can be found here. Insiders sold 73,532 shares of company stock worth $5,101,386 over the last three months. 0.20% of the stock is currently owned by corporate insiders.
Several equities research analysts have recently issued reports on GILD shares. Sanford C. Bernstein cut Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $78.00 to $70.00 in a report on Thursday, February 6th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Sunday, February 9th. Raymond James cut Gilead Sciences from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the stock from $81.00 to $80.00 in a report on Wednesday, February 5th. Cowen restated a “buy” rating and set a $85.00 price objective on shares of Gilead Sciences in a report on Thursday, January 2nd. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Gilead Sciences in a report on Wednesday, February 5th. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and fifteen have given a buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Hold” and an average target price of $78.08.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Relative Strength Index
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.